ImmuCell (ICCC) CFO granted 120,000 stock options at $6.265

Rhea-AI Filing Summary

ImmuCell Corporation filed a Form 4 for Chief Financial Officer and director Timothy C. Fiori reporting a new stock option grant. On January 27, 2026, he received 120,000 stock options with an exercise price of $6.265 per share, held directly.

The option is intended to qualify as an incentive stock option to the maximum extent allowed under the Internal Revenue Code, with the remainder as a nonqualified option. It vests in three equal tranches of 40,000 options on each of the first, second, and third anniversaries of the grant date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fiori Timothy C

(Last) (First) (Middle)

C/O IMMUCELL CORPORATION

56 EVERGREEN DRIVE

(Street)

PORTLAND ME 04103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ ICCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$6.265	01/27/2026		A		120,000		(1)	01/27/2036	Common Stock	120,000	$0	120,000	D

Explanation of Responses:

1. Option grant made to Mr. Fiori in connection with his employment as Chief Financial Officer. The option shall be treated as an incentive stock option to the maximum extent permitted by the International Revenue Code of 1986, as amended, with the balance treated as a nonqualified stock option. The stock option vests as follows: 40,000 options on the first, second and third anniversary of the grant date.

	/s/ Timothy C. Fiori	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ImmuCell (ICCC) report for Timothy C. Fiori?

ImmuCell reported a grant of 120,000 stock options to Chief Financial Officer and director Timothy C. Fiori. The options were granted on January 27, 2026, and give him the right to buy ImmuCell common stock at a fixed exercise price.

What are the key terms of Timothy C. Fiori’s ImmuCell (ICCC) stock options?

Timothy C. Fiori received 120,000 stock options with an exercise price of $6.265 per share. The grant is in connection with his role as Chief Financial Officer and is held directly by him as reported on the Form 4 filing.

How do Timothy C. Fiori’s ImmuCell (ICCC) stock options vest?

The 120,000 stock options vest over three years. The vesting schedule is 40,000 options on the first anniversary of the January 27, 2026 grant date, 40,000 on the second anniversary, and 40,000 on the third anniversary.

Are Timothy C. Fiori’s ImmuCell (ICCC) options incentive stock options?

The grant is intended to be treated as an incentive stock option to the maximum extent permitted by the Internal Revenue Code of 1986. Any remaining portion that cannot qualify will be treated as a nonqualified stock option under federal tax rules.

What position does Timothy C. Fiori hold at ImmuCell (ICCC) in this Form 4?

In this filing, Timothy C. Fiori is identified as both a director and an officer of ImmuCell Corporation. His officer title is Chief Financial Officer, and the stock option grant is described as being made in connection with his employment in that role.

How many ImmuCell (ICCC) derivative securities does Timothy C. Fiori own after this grant?

Following the reported transaction, Timothy C. Fiori beneficially owns 120,000 derivative securities in the form of stock options. These options provide the right to acquire an equal number of ImmuCell common shares, subject to the vesting schedule and exercise price terms.